Pharmaceutical - Johnson & Johnson, Boehringer Ingelheim, Tresiba

UK NICE recommends Giotrif and Velcade, but says “no” to added use of Alimta

23-04-2014

People in England and Wales with lung cancer whose tumors test positive for a mutation will now have…

AlimtaBoehringer IngelheimEli LillyGiotrifJohnson & JohnsonNorthern EuropeOncologyPharmaceuticalPricingRegulationUKVelcade

AASLD meeting highlights: Gilead’s sofosbuvir, Janssen’s simeprevir and Boehringer’s faldaprevir

03-11-2013

Among research results released at this week at the 64th Annual Meeting of the American Association for…

Anti-viralsBiotechnologyBoehringer IngelheimfaldaprevirGilead SciencesJanssenJohnson & JohnsonPharmaceuticalResearchsimeprevirsofosbuvir

Pipeline anti-diabetic drugs could challenge market-leaders, says Datamonitor

04-07-2013

Pipeline anti-diabetic drugs, including products from US drug major Eli Lilly (NYSE: LLY) and French…

albiglutideAmylinBoehringer IngelheimBydureonDiabetesdulaglutideEli LillyempagliflozinGlaxoSmithKlineInvokanaJohnson & JohnsonLantusNovo NordiskPharmaceuticalSanofiTresibaVictoza

Top drugmakers set up non-profit TransCelerate to speed pharma R&D

20-09-2012

Some of the world's leading pharmaceutical companies have formed a non-profit organization to accelerate…

Abbott LaboratoriesAstraZenecaBiotechnologyBoehringer IngelheimBristol-Myers SquibbEli LillyGlaxoSmithKlineJohnson & JohnsonPfizerPharmaceuticalRegulationResearchRocheSanofiTransCelerate BioPharma

Flood of new cancer drug data presented at ASCO; nearly 1,000 being tested

04-06-2012

The annual prestigious American Society of Clinical Oncology (ASCO) meeting taking place in Chicago,…

afatinibBiotechnologyBoehringer IngelheimGenentechJanssenJohnson & JohnsonOncologyPharmaceuticalResearchRochetrastuzumab emtansineZytiga

UK academia-pharma collaboration attracts £14.4 million funding

13-05-2012

In the UK, the University of Dundee and the Medical Research Council (MRC) have announced new funding…

AstraZenecaBoehringer IngelheimEuropeFinancialGlaxoSmithKlineJohnson & JohnsonMerck SeronoPfizerPharmaceuticalResearch

Caelyx and Ceplene manufacturing should be moved, says EMA

18-03-2012

The European Medicines Agency has recommended that the manufacturing processes for the anticancer medicines…

Boehringer IngelheimCaelyxCepleneEpiCeptJanssen-CilagJohnson & JohnsonOncologyPharmaceuticalRegulationRespiratory and Pulmonary

Parexel

Parexel

Back to top